Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Neurology

Journal Scan / Research · September 14, 2021

Intranasal Dihydroergotamine Mesylate for Acute Migraine Treatment



Additional Info

Disclosure statements are available on the authors' profiles:

STOP 301: A Phase 3, Open-Label Study of Safety, Tolerability, and Exploratory Efficacy of INP104, Precision Olfactory Delivery (POD® ) of Dihydroergotamine Mesylate, Over 24/52 Weeks in Acute Treatment of Migraine Attacks in Adult Patients
Headache 2021 Aug 07;[EPub Ahead of Print], TR Smith, P Winner, SK Aurora, M Jeleva, J Hocevar-Trnka, SB Shrewsbury

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading